Esperion Therapeutics, Inc. Announces Positive Top-Line Results From Phase 2 Clinical Study of Novel Oral Therapy in Patients With Hypercholesterolemia and a History of Statin Intolerance

Published: Jun 07, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PLYMOUTH, Mich.--(BUSINESS WIRE)--Esperion Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced positive top-line results from a Phase 2a clinical study of its lead product candidate ETC-1002 in patients with hypercholesterolemia with a history of intolerance to two or more statins. The study met its primary endpoint, demonstrating that ETC-1002 lowered LDL-C by an average of 32 percent and was well tolerated. These data will be submitted for presentation at a future medical meeting and for publication in a peer-reviewed journal.

Help employers find you! Check out all the jobs and post your resume.

Back to news